112 related articles for article (PubMed ID: 14675355)
1. Effective weekly docetaxel for recurrent ovarian cancer: A case report.
Komiyama S; Mizusawa Y; Onouchi M; Takehara K; Suzuki A; Mikami M
Int J Gynecol Cancer; 2003; 13(5):683-6. PubMed ID: 14675355
[TBL] [Abstract][Full Text] [Related]
2. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
[TBL] [Abstract][Full Text] [Related]
3. [First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer].
Lehoczky O; Pulay T
Magy Onkol; 2006; 50(1):43-6. PubMed ID: 16617383
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Komiyama S; Tsuji H; Asai S; Dokoh J; Ishikawa M; Mikami M
Eur J Gynaecol Oncol; 2005; 26(3):299-302. PubMed ID: 15991531
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
6. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.
Karasawa K; Katsui K; Seki K; Kohno M; Hanyu N; Nasu S; Muramatsu H; Maebayashi K; Mitsuhashi N; Haga S; Kimura T; Takahashi I
Breast Cancer; 2003; 10(3):268-74. PubMed ID: 12955041
[TBL] [Abstract][Full Text] [Related]
8. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
9. A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.
Oishi T; Kigawa J; Fujiwara K; Fujiwara M; Numa F; Aotani E; Katsumata N; Kohno I; Kato H; Terakawa N;
Gynecol Oncol; 2003 Aug; 90(2):421-4. PubMed ID: 12893211
[TBL] [Abstract][Full Text] [Related]
10. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
Niwa Y; Nakanishi T; Kuzuya K; Nawa A; Mizutani S
Int J Clin Oncol; 2003 Dec; 8(6):343-7. PubMed ID: 14663634
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.
Ghamande S; Lele S; Marchetti D; Baker T; Odunsi K
Int J Gynecol Cancer; 2003; 13(2):142-7. PubMed ID: 12657114
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA
Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
[TBL] [Abstract][Full Text] [Related]
17. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
19. [Results of docetaxel therapy in patients with relapsed ovarian cancer].
Lehoczky O; Thurzó L; Bagaméri A; Sárosi Z; Udvary J; Pulay T
Magy Onkol; 2005; 49(1):71-5. PubMed ID: 15902338
[TBL] [Abstract][Full Text] [Related]
20. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
